FDA, sleep apnea

FDA approves Zepbound for sleep apnea in obese adults
Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over time.
FDA approves new drug for sleep apnea
The third ‘Downton Abbey’ film honors the late Dame Maggie Smith and her iconic portrayal of Violet Crawley. The drug is known as Zepbound and is the same as the chemical drug Tirzepatide.
FDA Approves First Medication for Obstructive Sleep Apnea
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP machines remain the first-line treatment.
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.
FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
Gal-475 by Neurim Pharmaceuticals for Sleep Apnea: Likelihood of Approval
Gal-475 is under clinical development by Neurim Pharmaceuticals and currently in Phase I for Sleep Apnea. According to GlobalData, Phase I drugs for Sleep Apnea have a 96% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.
Zepbound Approved for Obstructive Sleep Apnea in Patients With Obesity
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
GLP-1 Zepbound is approved as first drug for sleep apnea
The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating obstructive sleep apnea (OSA): the weight-loss drug Zepbound.
Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to severe OSA in people with obesity.
Weight loss drug Zepbound approved to help sleep apnea patients
Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults earlier this month. “This is a major step forward for patients with obstructive sleep apnea,
Health Beat: Sleep disorders in the Hispanic community
According to the Hispanic Community Health Study, 14% of Hispanic men and 6% of Hispanic women have sleep apnea. With so many ...
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
Bradford Era2h
BRMC’s Sleep Disorders Center achieves milestone in patient care
The sleep disorders center at Bradford Regional Medical Center (BRMC), a Kaleida Health facility, achieved a milestone in ...
New device to treat sleep apnea was life-changing for NMHS patient
For those who have tried unsuccessfully to use a CPAP machine to treat sleep apnea, the Inspire implant is a breakthrough ...